|Place of Origin||USA|
|Technical Information||View technical data|
Configuration-specific monoclonal antibody that recognizes Cdc42-GTP, but not Cdc42-GDP
The only available Cdc42 activation assay kit directly measures the level of Cdc42-GTP
Providing reliable results with consistent reproducibility than other Cdc42 activation assay kits based on certain downstream signaling pathways
Providing shorter experimental time
Could be used to monitor the activation of Cdc42 in cells and in tissues by immunohistochemistry
Small GTPases are a super-family of cellular signaling regulators. Cdc42 belongs to the Rho sub-family of GTPases that regulate cell motility, cell division, and gene transcription. GTP binding increases the activity of Cdc42, and the hydrolysis of GTP to GDP renders it inactive.
Currently the activation of Cdc42 proteins is assayed with the binding of GTP-bound Cdc42 to the p21-binding domain (PBD) of p21-activated protein kinase (PAK). This method is based on the observation that the active, GTP-bound Cdc42 (and Rac) could bind to the PBD of PAK. However, the reproducibility of this method is poor. This is partially due to the relatively quick hydrolysis of GTP to GDP during the assay procedure, and the low binding affinity of PBD to Cdc42-GTP.
NewEast Biosciences Cdc42 Activation Assay Kit is based on the configuration-specific monoclonal antibody that specifically recognizes Cdc42-GTP, but not Cdc42-GDP. Given the high affinity of monoclonal antibodies to their antigens, the activation assay could be performed in a much shorter time. This assay provides the reliable results with consistent reproducibility.
These anti-Cdc42-GTP monoclonal antibody can also be used to monitor the activation of Cdc42 in cells and in tissues by immunohistochemistry.
NewEast Biosciences Cdc42 Activation Assay Kit provides a simple and fast method to monitor the activation of Cdc42. Each kit provides sufficient quantities to perform 20 assays.
NewEast Biosciences Cdc42 Activation Assay Kit bases on the configuration-specific anti-Cdc42-GTP monoclonal antibody to measure the active Cdc42-GTP levels, either from cell extracts or from in vitro GTPγS loading Cdc42 activation assays. Briefly, anti-active Cdc42 mouse monoclonal antibody will be incubated with cell lysates containing Cdc42-GTP. The bound active Cdc42 will then be pulled down by protein A/G agarose. The precipitated active Cdc42 will be detected by immunoblot analysis using anti-Cdc42 rabbit polyclonal antibody.
|80701||Cdc42 Activation Assay Kit||20 assays||$737|
|26905||Active Cdc42-GTP Monoclonal Antibody||30 μL||$495|
|26008||Anti-Cdc42 Mouse Monoclonal Antibody||100 μL||$275|
|21010||Anti-Cdc42 Rabbit Polyclonal Antibody||100 μL||$275|
|1. Ethanol increases p190RhoGAP activity, leading to actin cytoskeleton rearrangements|
J Neurochem. 2011 Dec;119(6):1306-16
|2. The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1|
Oncogene. 2012 Aug 30;31(35):3913-23
|3. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation|
Carcinogenesis. 2010 Jul;31(7):1230-7
|4. Transgenesis of the Wolffian duct visualizes dynamic behavior of cells undergoing tubulogenesis in vivo|
Development, Growth & Differentiation. Volume 55, Issue 4, pages 579–590, May 2013
|5. Foxc2 induces Wnt4 and Bmp4 expression during muscle regeneration and osteogenesis|
Cell Death and Differentiation (2013) 20, 1031–1042
|6. N-glycosylation induces collagen triple helix repeat containing 1 (CTHRC1) and drives oral cancer cell migration|
J Biol Chem. 2013 Jul 12;288(28):20217-27
|7. Cyclodextrin protects podocytes in diabetic kidney disease|
Diabetes. 2013 Nov;62(11):3817-27
|8. Amyloid beta1-42 (Aβ42) up-regulates the expression of sortilin via the p75NTR/RhoA signaling pathway|
Journal of Neurochemistry Volume 127, Issue 2, pages 152–162, October 2013
|9. Podocyte-specific GLUT4 deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy|
Diabetes. 2014 Feb;63(2):701-14
|10. Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial–mesenchymal transition of cancer cells|
Cell Death and Disease (2013) 4, e848
|11. Syndecan-2 regulation of morphology in breast carcinoma cells is dependent on RhoGTPases|
Biochimica et Biophysica Acta (BBA) - General Subjects Volume 1840, Issue 8, August 2014, Pages 2482–2490
|12. Epithelial repair is a two-stage process driven first by dying cells and then by their neighbours|
J Cell Sci. 2014 Mar 15;127(Pt 6):1229-41
|13. MIF inhibits monocytic movement through a non-canonical receptor and disruption of temporal Rho GTPase activities in U-937 cells|
Cytokine Volume 69, Issue 1, September 2014, Pages 47–55
|14. Triclosan Potentiates Epithelial-To-Mesenchymal Transition in Anoikis-Resistant Human Lung Cancer Cells|
PLoS One. 2014 Oct 16;9(10):e110851